Attorney Advertising. The law firm of Wolf Haldenstein Adler Freeman & Herz LLP is investigating possible breaches of fiduciary duty by the Board of Directors of Pharmaceutical Product Development, Inc. (“PPDI” or the “Company”) [NASDAQ:PPDI] arising out of the proposed acquisition of PPDI by The Carlyle Group and Hellman & Friedman (“Carlyle/Hellman”).

On Monday, October 3, 2011, PPDI announced that Carlyle/Hellman will acquire PPDI pursuant to an all cash offer. Under the terms of the agreement, PPDI stockholders will receive cash of $33.25 in exchange for each share of PPDI common stock. However, the Company may not have adequately shopped itself before entering into this transaction and, pursuant to this proposed transaction, Carlyle/Hellman may be underpaying for PPDI, thus unlawfully harming PPDI shareholders.

Wolf Haldenstein has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in U.S. federal and state courts. Please visit the Wolf Haldenstein website (http://www.whafh.com) for more information about the firm.

If you own PPDI common stock and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.